Skip to content

Detailed immunotyping of immune-mediated inflammatory diseases (IMIDs) by investigating cellular and molecular biomarkers in blood and synovial fluid

Detailed immunotyping of immune-mediated inflammatory diseases (IMIDs) by investigating cellular and molecular biomarkers in blood and synovial fluid - Immunotyping of IMIDs in blood and synovial fluid

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON55821
Enrollment
700
Registered
2018-04-13
Start date
2019-02-14
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arthritis systemic inflammatory diseases

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - patients with clinically suspected arthralgia or a diagnosis of an immune-mediated inflammatory disease - patients must be 18 years or older

Exclusion criteria

Exclusion criteria: - patients unable to give informed consent

Design outcomes

Primary

MeasureTime frame
To identify immunological alterations in the PB and SF of patients with various forms of established or early forms of immune-mediated inflammatory diseases and to correlate these alterations with diagnosis, disease stage, prognosis, and treatment response and compare this to healthy controls. We thereby aim to identify and validate novel biomarkers that can be used for personalized medicine in IMIDs

Secondary

MeasureTime frame
n.a.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)